Cryptococcosis is an invasive mycosis caused mainly by Cryptococcus gattii and C. neoformans and is treated with amphotericin B (AMB), fluconazole and 5-fluorocytosine. However, antifungal resistance, limited and toxic antifungal arsenal stimulate the search for therapeutic strategies such as drug repurposing. Among the repurposed drugs studied, the selective serotonin reuptake inhibitors (SSRIs) have shown activity against Cryptococcus spp. However, little is known about the antifungal effect of duloxetine hydrochloride (DH), a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), against C. neoformans and C. gattii. In this study, DH inhibited the growth of several C. neoformans and C. gattii strains at concentrations ranging from 15.62 to 62.50 µg/mL. In addition, DH exhibited fungicidal activity ranging from 15.62 to 250 µg/mL. In biofilm, DH treatment reduced Cryptococcus spp. biomass at a level comparable to AMB, with a significant reduction (85%) for C. neoformans biofilms. The metabolic activity of C. neoformans and C. gattii biofilms decreased significantly (99%) after treatment with DH. Scanning electron micrographs confirmed the anti-biofilm activity of DH, as isolated cells could be observed after treatment. In conclusion, DH showed promising antifungal activity against planktonic cells and biofilms of C. neoformans and C. gattii, opening perspectives for further studies with DH in vivo.

Department of Biosciences and Oral Diagnosis Institute of Science and Technology São Paulo State University Av Engenheiro Francisco José Longo 777 São José dos Campos São Paulo 12245 000 Brazil

Universidade de Guarulhos Programa de Pós Graduação em Enfermagem Guarulhos SP Brasil

Zobrazit více v PubMed

Almeida F, Wolf JM, Casadevall A (2015) Virulence-associated enzymes of Cryptococcus neoformans. Eukaryot Cell 14(12):1173–1185. https://doi.org/10.1128/EC.00103-15 PubMed DOI PMC

Almeida-Paes R, Frases S (2023) Repurposing drugs for fungal infections: advantages and limitations. Future Microbiol. https://doi.org/10.2217/fmb-2023-0108 PubMed DOI

Alves V, Martins PH, Miranda B, de Andrade IB, Pereira L, Maeda CT, de Sousa Araújo GR, Frases S (2023) Assessing the in vitro potential of glatiramer acetate (copaxone DOI

Arendrup MC, Meletiadis J, Mouton JW, Lagrou K, Hamal P, Guinea J, AFST/ESCMID/EUCAST (2017) EUCAST DEFINITIVE DOCUMENT E.DEF 7.3.1. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. 1–21. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_7_3_1_Yeast_testing__definitive.pdf

Barbosa JO, Rossoni RD, Vilela SFG, De Alvarenga JA, Velloso MDS, Prata MCDA, Jorge AOC, Junqueira JC (2016) Streptococcus mutans can modulate biofilm formation and attenuate the virulence of Candida albicans. PLoS ONE 11(3):e0150457. https://doi.org/10.1371/journal.pone.0150457 PubMed DOI PMC

Borrelli F, Izzo AA (2009) Herb–drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 11:710–727. https://doi.org/10.1208/s12248-009-9146-8 PubMed DOI PMC

Cassetta MI, Marzo T, Fallani S, Novelli A, Messori L (2014) Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals 27(4):787–791. https://doi.org/10.1007/s10534-014-9743-6 PubMed DOI

Chastain DB, Kung VM, Vargas Barahona L, Jackson BT, Golpayegany S, Franco-Paredes C, Thompson GR, Henao-Martínez AF (2022) Characteristics and outcomes of cryptococcosis among patients with and without COVID-19. J Fungi 8(11):1234. https://doi.org/10.3390/jof8111234 DOI

Chen T, Mwenge L, Lakhi S, Chanda D, Mwaba P, Molloy SF, Gheorghe A, Griffiths UK, Heyderman RS, Kanyama C, Kouanfack C, Mfinanga S, Chan AK, Temfack E, Kivuyo S, Hosseinipour MC, Lortholary O, Loyse A, Jaffar S, Niessen LW (2019) Healthcare costs and life-years gained from treatments within the advancing cryptococcal meningitis treatment for africa (ACTA) trial on cryptococcal meningitis: a comparison of antifungal induction strategies in sub-saharan africa. Clin Infect Dis 69(4):588–595. https://doi.org/10.1093/cid/ciy971 PubMed DOI PMC

Costa Silva RA, da Silva CR, de Andrade Neto JB, da Silva AR, Campos RS, Sampaio LS, do Nascimento FBSA, da Silva Gaspar B, da Cruz Fonseca SG, Josino MAA, Grangeiro TB, Gaspar DM, de Lucena DF, de Moraes MO, Cavalcanti BC, Nobre Júnior HV (2017) In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates. Microb Pathog 107:341–348. https://doi.org/10.1016/j.micpath.2017.04.008 PubMed DOI

da Silva CR, do Amaral Valente Sá LG, Ferreira TL, Leitão AC, de Farias Cabral VP, Rodrigues DS, Barbosa AD, Moreira LEA, Filho HLP, de Andrade Neto JB, Rios MEF, Cavalcanti BC, Magalhães HIF, de Moraes MO, Nobre HV (2023) Antifungal activity of selective serotonin reuptake inhibitors against Cryptococcus spp and their possible mechanism of action. J Med Mycol 33(4):101431. https://doi.org/10.1016/j.mycmed.2023.101431 DOI

Deng H, Song J, Huang Y, Yang C, Zang X, Zhou Y, Li H, Dai B, Xue X (2023) Combating increased antifungal drug resistance in Cryptococcus, what should we do in the future? Acta Biochim Biophys Sin 55(4):540–547. https://doi.org/10.3724/abbs.2023011 PubMed DOI PMC

Feng X, Fu X, Ling B, Wang L, Liao W, Yao Z (2013) Development of a singleplex PCR assay for rapid identification and differentiation of Cryptococcus neoformans var. grubii, Cryptococcus neoformans var. neoformans, Cryptococcus gattii, and hybrids. J Clin Microbiol 51(6):1920–1923. https://doi.org/10.1128/JCM.00064-13 PubMed DOI PMC

Freitas GJC, Ribeiro NQ, Gouveia-Eufrasio L, Emidio ECP, Guimarães GM, César IC, Paixão TA, Oliveira JBS, Caza M, Kronstad JW, Santos DA (2023) Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis. Int J Antimicrob Agents 62(1):106807. https://doi.org/10.1016/j.ijantimicag.2023.106807 PubMed DOI

Hazen KC (1998) Fungicidal versus fungistatic activity of terbinafine and itraconazole: An in vitro comparison. J Am Acad Dermatol 38(5):S37–S44. https://doi.org/10.1016/S0190-9622(98)70482-7 PubMed DOI

Kane A, Carter DA (2022) Augmenting azoles with drug synergy to expand the antifungal toolbox. Pharmaceuticals 15(4):482. https://doi.org/10.3390/ph15040482 PubMed DOI PMC

Katende A, Mbwanji G, Faini D, Nyuri A, Kalinjuma AV, Mnzava D, Hullsiek KH, Rhein J, Weisser M, Meya DB, Boulware DR, Letang E (2019) Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. Mycoses 62(12):1127–1132. https://doi.org/10.1111/myc.12995 PubMed DOI PMC

Laniado-Laborín R, Cabrales-Vargas MN (2009) Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26(4):223–227. https://doi.org/10.1016/j.riam.2009.06.003 PubMed DOI

Martinez LR, Casadevall A (2006) Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 50(3):1021–1033. https://doi.org/10.1128/AAC.50.3.1021-1033.2006 PubMed DOI PMC

Martinez LR, Casadevall A (2015) Biofilm formation by Cryptococcus neoformans. Microbiol Spectr 3(3). https://doi.org/10.1128/microbiolspec.MB-0006-2014

Menezes RT, Pereira TC, Junqueira JC, Oliveira LD, Scorzoni L (2022) Synergistic combination of duloxetine hydrochloride and fluconazole reduces the cell growth and capsule size of Cryptococcus neoformans. Anais Da Academia Brasileira de Ciências 94(2):e20211021. https://doi.org/10.1590/0001-3765202220211021 PubMed DOI

Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discovery 8(12):959–968. https://doi.org/10.1038/nrd2961 PubMed DOI

Nochaiwong S, Ruengorn C, Awiphan R, Chai-Adisaksopha C, Tantraworasin A, Phosuya C, Kanjanarat P, Chongruksut W, Sood MM, Thavorn K (2022) Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med 54(1):80–97. https://doi.org/10.1080/07853890.2021.2017474 PubMed DOI

Oprea TI, Mestres J (2012) Drug repurposing: far beyond new targets for old drugs. AAPS J 14(4):759–763. https://doi.org/10.1208/s12248-012-9390-1 PubMed DOI PMC

Paulzen M, Gründer G, Veselinovic T, Wolf B, Hiemke C, Lammertz SE (2016) Duloxetine enters the brain–But why is it not found in the cerebrospinal fluid. J Affect Disord 189:159–163. https://doi.org/10.1016/j.jad.2015.08.073 PubMed DOI

Peeters E, Nelis HJ, Coenye T (2008) Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 72(2):157–165. https://doi.org/10.1016/j.mimet.2007.11.010 PubMed DOI

Pereira TC, De Menezes RT, De Oliveira HC, De Oliveira LD, Scorzoni L (2021) In vitro synergistic effects of fluoxetine and paroxetine in combination with amphotericin B against Cryptococcus neoformans. Pathog Dis 79(2):ftab001. https://doi.org/10.1093/femspd/ftab001 PubMed DOI

Periyasami G, Karuppiah P, Karthikeyan P, Palaniappan S (2023) Anti-infective efficacy of duloxetine against catheter-associated urinary tract infections caused by gram-positive bacteria. ACS Ômega 8(50):48317–48325. https://doi.org/10.1021/acsomega.3c07676 PubMed DOI PMC

Preskorn SH (2004) Duloxetine. J Psychiatr Pract 10(6):375–385. https://doi.org/10.1097/00131746-200411000-00006 PubMed DOI

Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, Denning DW, Meya DB, Chiller TM, Boulware DR (2022) The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis 22(12):1748–1755. https://doi.org/10.1016/S1473-3099(22)00499-6 PubMed DOI PMC

Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY (2008) Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104(4):289–298. https://doi.org/10.1111/j.1600-0447.2001.00263.x DOI

Rathore SS, Sathiyamoorthy J, Lalitha C, Ramakrishnan J (2022) A holistic review on Cryptococcus neoformans. Microb Pathog 166:105521. https://doi.org/10.1016/j.micpath.2022.105521 PubMed DOI

Ribeiro NQ, Santos APN, Emídio ECP, Costa MC, Freitas GJC, Carmo PHF, Silva MF, de Brito CB, de Souza DG, Paixão TA, Santos DA (2019) Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis. Int J Antimicrob Agents 54(3):301–308. https://doi.org/10.1016/j.ijantimicag.2019.06.020 PubMed DOI

Rizea-Savu S, Duna SN, Ghita A, Iordachescu A, Chirila M (2020) The effect of food on the single-dose bioavailability and tolerability of the highest marketed strength of duloxetine. Clin Pharmacol Drug Dev 9(7):797–804. https://doi.org/10.1002/cpdd.759 PubMed DOI

Rodrigues DS, Cabral VPF, Barbosa AD, Sá LGDAV, Moreira LEA, de Andrade Neto JB, da Silva CR, de Moraes MO, Silva J, Marinho ES, Dos Santos HS, da Costa ÉRM, Silveira MJCB, E Silva LH, Nobre Júnior HV (2023) Sertraline has in vitro activity against both mature and forming biofilms of different Candida species. J Med Microbiol 72(2). https://doi.org/10.1099/jmm.0.001664 . PMID: 36762524

Rossato L, Loreto ÉS, Zanette RA, Chassot F, Santurio JM, Alves SH (2016) In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii. Folia Microbiologica 61(5):399–403. https://doi.org/10.1007/s12223-016-0449-8 PubMed DOI

Salem HF, Ali AA, Rabea YK, El-Ela FIA, Khallaf RA (2022) Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal. Drug Deliv Transl Res 12(12):3083–3103. https://doi.org/10.1007/s13346-022-01172-z PubMed DOI PMC

Spandana KA, Bhaskaran M, Karri VR, Natarajan J (2020) A comprehensive review of nano drug delivery system in the treatment of CNS disorders. J Drug Deliv Sci Technol 57:101628. https://doi.org/10.1016/j.jddst.2020.101628 DOI

Treviño-Rangel RDJ, Villanueva-Lozano H, Hernández-Rodríguez P, Martínez-Reséndez MF, García-Juárez J, Rodríguez-Rocha H, González GM (2016) Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays. Med Mycol 54(3):280–286. https://doi.org/10.1093/mmy/myv109 PubMed DOI

Vey EL, Kovelman I (2010) Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey. J Forensic Leg Med 17(4):175–185. https://doi.org/10.1016/j.jflm.2010.02.002 PubMed DOI

Waitekus AB, Kirkpatrick P (2004) Duloxetine hydrochloride. Nat Rev Drug Discov 3(11):907–908. https://doi.org/10.1038/nrd1555 PubMed DOI

Wang Y, Pawar S, Dutta O, Wang K, Rivera A, Xue C (2022) Macrophage mediated immunomodulation during cryptococcus pulmonary infection. Front Cell Infect Microbiol. https://doi.org/10.3389/fcimb.2022.859049 PubMed DOI PMC

Zhai B, Wu C, Wang L, Sachs MS, Lin X (2012) The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother 56(7):3758–3766. https://doi.org/10.1128/AAC.00212-12 PubMed DOI PMC